|
|
 |
Fact Sheet
Faster Time to Resolution of Diarrhea with Fidaxomicin vs. Vancomycin in Patients with Clostridium difficile Infection (CDI), poster presented at the 47th IDSA annual meeting, October 2009
Effect of Concomitant Antibiotics on Treatment of Clostridium difficile (CDI) Infection with Fidaxomicin or Vancomycin
Age, Serum Albumin, and Leukocytosis/Fever Predict Clinical Outcomes, poster presented at the 47th IDSA annual meeting, October 2009
Low Recurrence Rate among Patients with C. difficile Infection (CDI) Treated with Fidaxomicin (FDX), poster presented at the 49th ICAAC, September 2009
Restriction Endonuclease Analysis (REA) Typing of Clostridium difficile in a Phase 3 Treatment Trial of Fidaxomicin vs Vancomycin: Decreased Cure Rate for Epidemic BI/NAP1/027 Strain, poster presented at the 49th ICAAC, September 2009
Comparative Fidaxomicin Susceptibilities of Isolates Collected at Baseline, Failure, and Recurrence from Patients in a Phase III Trial of Clostridium difficile Infection (CDI), poster presented at the 49th ICAAC, September 2009
Pharmacokinetics/Pharmacodynamics (PK/PD) of Fidaxomicin in Treatment of Clostridium difficile Infection (CDI), poster presented at the 49th ICAAC, September 2009
Safety of Fidaxomicin Versus Vancomycin in Treatment of Clostridium difficile Infection, poster presented at the 49th ICAAC, September 2009
Typing and Susceptibility of Bacterial Isolates from the OPT-80 (PAR-101) Phase 2A Study for C. Difficile-associated Diarrhea, presented at the 9th Biennial Congress of the Anaerobe Society of the Americas, June 2008
Narrow Spectrum Activity and Low Fecal Binding of OPT-80 and Its Major Hydrolysis Metabolite (OP-1118), poster presented at the 47th ICAAC, an annual meeting of the American Society for Microbiology, September 2007
PAR-101 is selectively effective against Clostridium difficile in-vivo and has minimal effect on the anaerobic fecal flora, poster presented at the 45th ICAAC, an annual meeting of the American Society for Microbiology, December 2005
OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides
Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a
Effect of Inoculum, pH, and Cations on the In vitro Activity of OPT-80 vs. Clostridium difficile, poster presented at the 45th ICAAC, an annual meeting of the American Society for Microbiology, December 2005
Safety, Pharmacokinetics and Outcomes of PAR-101 in Healthy Subjects and Patients with Clostridium difficile-Associated Diarrhea (CDAD), poster presented at the 45th ICAAC, an annual meeting of the American Society for Microbiology, December 2005
Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy
Safety and Pharmacokinetics of OPT-80 in Human Volunteers, poster presented at the 44th ICAAC, an annual meeting of the American Society for Microbiology, October 2004
Antimicrobial Activity and Post-Antibiotic Effect (PAE) of OPT-80, a New Macrocyclic Compound, against Clostridium difficile, poster presented at the 44th ICAAC, an annual meeting of the American Society for Microbiology, October 2004
Resistance Development, Cross Resistance, and Synergy Studies of OPT-80, poster presented at the 44th ICAAC, an annual meeting of the American Society for Microbiology, October 2004
Safety and Pharmacokinetics of OPT-80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD), poster presented at the 44th ICAAC, an annual meeting of the American Society for Microbiology, October 2004
|
|
|
|
![](images/spacer.gif"){kind=spacer}
PDF